Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

K. Van Besien,Armando A. Rodríguez,S. Tomany,A. Younes,M. Donato,Andreas H. Sarris,Sergio Giralt,R. Mehra,Borje S Andersson,James Gajewski,Richard E Champlin,Fernando Cabanillas

Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

2001

K. Van Besien
Armando A. Rodríguez
S. Tomany
A. Younes
M. Donato
Andreas H. Sarris
Sergio Giralt
R. Mehra
Borje S Andersson
James Gajewski
Richard E Champlin
Fernando Cabanillas

Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

Keywords:

Etoposide
Immunology
Ifosfamide
Antimetabolite
Phases of clinical research
Transplantation
Chemotherapy
Medicine
Nitrogen mustard
Chemotherapy regimen
Aggressive lymphoma
Regimen
Autologous stem-cell transplantation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations